Core Viewpoint - The financial performance of Changshan Pharmaceutical (300255) for the first half of 2025 shows a decline in revenue and an increase in net loss, indicating financial stress and operational challenges [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 492 million yuan, a decrease of 13.42% compared to the same period in 2024 [1]. - The net profit attributable to shareholders was -29.09 million yuan, an improvement of 37.98% year-on-year [1]. - The gross margin was 14.54%, down 8.28% year-on-year, while the net margin was -7.37%, an increase of 10.82% [1]. - The total of selling, administrative, and financial expenses was 104 million yuan, accounting for 21.19% of revenue, a decrease of 12.23% year-on-year [1]. - The current ratio was 0.79, indicating increased short-term debt pressure [1]. Key Financial Metrics - Cash and cash equivalents decreased by 35.71% to 218 million yuan [3]. - Accounts receivable increased by 10.89% to 332 million yuan [3]. - Interest-bearing liabilities rose by 2.95% to 2.461 billion yuan [3]. - Earnings per share improved to -0.03 yuan, a 40% increase year-on-year [1]. Operational Insights - The decline in revenue was attributed to decreased sales of heparin raw materials and low molecular weight heparin preparations [3]. - Significant changes in financial items included a 30.92% increase in accounts receivable and a 26.21% increase in short-term borrowings [3]. - The company experienced a 65.43% reduction in selling expenses due to changes in marketing strategies [3]. Cash Flow and Debt Analysis - The net cash flow from operating activities decreased by 13.95%, primarily due to reduced cash receipts from sales [3]. - The company’s cash flow situation is concerning, with cash and cash equivalents only covering 10.07% of current liabilities [5]. - The interest-bearing debt ratio reached 53.42%, indicating a high level of leverage [5]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 7.03% over the past decade and a particularly poor ROIC of -23.95% in 2023 [4]. - The company has reported losses in two of the last ten years, reflecting a fragile business model [4].

Core Insights - The company has shown initial success in its strategic transformation, with a significant reduction in sales and management expenses leading to a narrowing of net profit loss by 37.98% year-on-year [1][2] Financial Performance - The company reported operating revenue of 492 million yuan, with a net profit attributable to shareholders of -29.09 million yuan, a year-on-year improvement of 37.98% [2] - The net cash flow from operating activities reached 173 million yuan, demonstrating strong cash collection capabilities despite a slight year-on-year decline of 13.95% [2] - The debt structure has improved, with a stable debt-to-asset ratio of 67% and long-term loans reduced to 4.358 billion yuan [2] Innovation Pipeline - The core product, Aibennate, has made significant progress in diabetes and weight loss indications, with its New Drug Application (NDA) for diabetes already accepted by the National Medical Products Administration [3] - Aibennate is expected to enter the market soon, targeting a global market exceeding 100 billion USD for weight loss drugs by 2030 [3] - The company is also advancing its second key product, CSCJC3456, an FGFR inhibitor, which is currently in Phase I clinical trials for advanced malignant tumors [3][4] Cost Management and International Expansion - The company has achieved cost reductions in its heparin business, with a self-supply rate of 65% for heparin crude products, leading to a 12% reduction in per-ton costs compared to external purchases [5] - The export revenue from heparin sodium injection has increased by 21% year-on-year, supported by registrations in countries like Tanzania and Belarus [5] - The company has established multiple national and provincial research platforms, with a total of 108 invention patents, enhancing its innovation and international competitiveness in the biopharmaceutical sector [5]

智通财经APP讯，常山药业(300255.SZ)发布2025年半年度报告，该公司营业收入为4.92亿元，同比减少 13.42%。归属于上市公司股东的净亏损为2908.9万元，同比收窄37.98%。归属于上市公司股东的扣除非 经常性损益的净亏损为3025.89万元，同比收窄43.62%。基本每股亏损为0.03元。 ...

Core Insights - The company reported a revenue of 492 million yuan for the first half of 2025, representing a year-on-year decline of 13.42% [1] - The net profit attributable to shareholders of the listed company was -29.09 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -30.26 million yuan [1] - The basic earnings per share were -0.03 yuan [1]

河北常山生化药业股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范河北常山生化药业股份有限公司（以下简称"公司"）信息 披露暂缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资者的合法 权益，根据《上市公司信息披露管理办法》《上市公司信息披露暂缓与豁免管理 规定》《深圳证券交易所创业板股票上市规则》等法律法规和《公司章程》的规 定，结合公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会（以下简称"中国证监会"）和证 券交易所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操纵市场等违法行为。 第四条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事项， 履行内部审核程序后实施。暂缓、豁免事项的范围原则上应当与公司股票首次在 证券交易所上市时保持一致，在上市后拟增加暂缓、豁免披露事项的，应当有确 实充分的证据。 第二章 暂缓、豁免披露信息的范围及其管理 ...

编制单位：河北常山生化药业股份有限公司 单位：人民币万元 河北常山生化药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表 2025 年半年度 | | 石家庄常山大药房 | 全资子公司 | 其他应收款 | 371.01 | | | 200.00 | 171.01 | 往来款 | 非经营性往 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 有限公司 | | | | | | | | | 来 | | | 河北常山凯拉生物 技术有限公司 | 全资子公司 | 其他应收款 | 210.00 | 208.40 | | 190.00 | 228.40 | 往来款 | 非经营性往 来 | | | 石家庄新华常山药 业血液透析中心 | 设立的民间 非营利性组 织 | 其他应收款 | 2,394.89 | 300.00 | | | 2,694.89 | 往来款 | 非经营性往 来 | | | CHANGSHANEUR OPESRL | 全资子公司 | 其他应收款 | 230.60 | 203.32 | | | 433.92 ...

本次会议经过充分讨论，以记名投票方式审议通过如下议案： 一、审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合法律、行 政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意；0 票反对；0 票弃权。 证券代码：300255 证券简称：常山药业 公告编号：2025-34 河北常山生化药业股份有限公司 第六届监事会第三次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"） 第六届监事会第三 次会议于 2025 年 8 月 22 日在公司办公楼会议室召开。本次会议于 2025 年 8 月 12 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会的各位 监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实际参与 表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，符合《公司法》及 《公司章程》等规定。 特此公告 ...

河 河北常山生化药 药业股份有限公 司 2025 年半年度报告全文 河北常山生化 化药业股 股份有限 限公司 2025 年 年半年度 度报告 2025-36 202 25 年 8 月 月 1 河北常山生化药业股份有限公司 2025 年半年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人高晓东、主管会计工作负责人岳晓华及会计机构负责人(会计 主管人员)岳晓华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意公司在生产经 营中可能存在的政策及行业风险、药品带量采购风险、市场竞争加剧风险、 新产品研发风险等风险，有关风险因素内容与对策举措已在本报告中第三节 "管理层讨论与分析"之"十、公司面临的 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-33 河北常山生化药业股份有限公司（以下简称"公司"）第六届董事会第三次 会议于 2025 年 8 月 22 日在公司办公楼会议室召开。本次会议于 2025 年 8 月 12 日以邮件或直接送达的方式确保每一位董事收到本次会议通知。与会的各位董事 均已知悉与所议事项相关的必要信息。会议应参与表决董事 6 名，实际参与表决 董事 6 名。本次会议由公司董事长高晓东先生主持，符合《公司法》及《公司章 程》等规定。 会议以记名投票方式对各项议案进行表决，审议通过如下议案： 一、审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 公司《2025 年半年度报告》内容真实、准确、完整地反映了公司 2025 年半 年度的经营情况，不存在虚假记载、误导性陈述或者重大遗漏。具体内容详见公 司同日发布的《2025 年半年度报告》。 公司《2025 年半年度报告》中的财务报告已经公司董事会审计委员会审议 通过。 表决结果：6 票同意；0 票反对；0 票弃权。 二、审议通过《关于制定<信息披露暂缓与豁免管理制度>的议案》 表决结果：6 票同意；0 票反对；0 ...

Market Overview - On August 20, the A-share market saw a rebound with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index all reaching new highs for the year. The Shanghai and Shenzhen markets had a total trading volume of 2.41 trillion yuan, a decrease of 180.1 billion yuan from the previous trading day, marking six consecutive days of over 2 trillion yuan in trading volume. Over 3,600 stocks rose in the market [2][3] - The Shanghai Composite Index increased by 1.04% to 3766.21 points, the Shenzhen Component Index rose by 0.89% to 11926.74 points, and the ChiNext Index gained 0.23% to 2607.65 points [3] Sector Performance - Chip stocks surged in the afternoon, while consumer stocks such as liquor rebounded. Consumer electronics also showed active performance. Conversely, high-priced stocks collectively fell, with sectors like film, chemical pharmaceuticals, CRO, and vitamins experiencing declines. The top-performing sectors included liquor, semiconductors, AI glasses, and minor metals, while the worst-performing sectors were film, chemical pharmaceuticals, CRO, and vitamins [2] International Market - In the U.S. stock market on August 20, the Dow Jones Industrial Average rose by 16.04 points (0.04%) to 44938.31 points, while the S&P 500 fell by 15.59 points (0.24%) to 6395.78 points, and the Nasdaq Composite dropped by 142.09 points (0.67%) to 21172.86 points [4][6] - In Europe, the FTSE 100 index increased by 98.92 points (1.08%) to 9288.14 points, while the CAC 40 index in France fell by 6.05 points (0.08%) to 7973.03 points, and the DAX index in Germany decreased by 146.10 points (0.60%) to 24276.97 points [4] Commodity Prices - International oil prices rose on August 20, with light crude oil futures for September delivery increasing by $0.86 (1.38%) to $63.21 per barrel, and Brent crude oil futures for October delivery rising by $1.05 (1.60%) to $66.84 per barrel [5] Automotive Market - According to the China Passenger Car Association, from August 1 to 17, the national retail sales of passenger cars reached 866,000 units, a year-on-year increase of 2%. Cumulatively, retail sales for the year reached 13.611 million units, up 10% year-on-year. The retail sales of new energy vehicles during the same period were 502,000 units, a year-on-year increase of 9% [11] Financial Regulations - The National Financial Regulatory Administration has proposed that the proportion of controlling mergers and acquisitions loans should not exceed 70% of the transaction price, while equity funds must account for at least 30%. This aims to mitigate high-leverage merger financing risks [8] Company Announcements - Muyuan Foods reported a net profit growth of 1170% year-on-year for the first half of the year, while Weicai Technology saw a net profit increase of 831% year-on-year. Tianwei Foods is planning to issue H-shares and list on the Hong Kong Stock Exchange [14]